pISSN 2234-3806
eISSN 2234-3814

Table. 3. Table 3

Comparison of plasma NGAL:hepcidin-25 versus other biomarkers at ICU admission for MAKE and AKI

Biomarkers at ICU admission (events: MAKE/AKI)	MAKE		AKI

	AUC (95% CI)	P	AUC (95% CI)	P
Plasma NGAL:hepcidin-25 vs. serum creatinine	0.79 (0.63–0.95);	0.599	0.89 (0.81–0.98);	0.051
(N = 8 of 97 patients/N = 7 of 97 patients)	0.72 (0.46–0.97)		0.63 (0.37–0.89)
Plasma NGAL:hepcidin-25 vs. urinary output	0.79 (0.63–0.95);	0.894	0.89 (0.81–0.98);	0.116
(N = 8 of 97 patients/N = 7 of 97 patients)	0.78 (0.62–0.93)		0.74 (0.56–0.92)
Plasma NGAL:hepcidin-25 vs. urinary protein	0.79 (0.63–0.95);	0.482	0.89 (0.81–0.98);	0.030
(N = 8 of 97 patients/N = 7 of 97 patients)	0.73 (0.57–0.88)		0.66 (0.45–0.88)
Plasma NGAL:hepcidin-25 vs. plasma NGAL	0.79 (0.63–0.95);	0.881	0.89 (0.81–0.98);	0.111
(N = 8 of 97 patients/N = 7 of 97 patients)	0.77 (0.57–0.88)		0.73 (0.54–0.93)
Plasma NGAL:hepcidin-25 vs. 1-plasma hepcidin-25^*	0.79 (0.63–0.95);	0.014	0.89 (0.81–0.98);	0.042
(N = 8 of 97 patients/N = 7 of 97 patients)	0.58 (0.38–0.78)		0.71 (0.52–0.91)
Plasma NGAL:hepcidin-25 vs. plasma IL-6	0.72 (0.45–0.99);	0.892	0.943 (0.88–0.99);	0.054
(N = 4 of 88 patients/N = 3 of 88 patients)	0.74 (0.53–0.96)		0.67 (0.39–0.95)
Plasma NGAL:hepcidin-25 vs. urinary NGAL:hepcidin-25	0.79 (0.63–0.95);	0.555	0.89 (0.81–0.98);	0.973
(N = 8 of 97 patients/N = 7 of 97 patients)	0.84 (0.66–0.99)		0.89 (0.80–0.98)

^*Indicates biomarker with inverse relationship to endpoints.

AUC of urinary NGAL:hepcidin-25 at ICU admission was used from a previous publication [16].

Abbreviations: AKI, acute kidney injury; AUC, area under the ROC curve; ICU, intensive care unit; IL, interleukin; MAKE, major adverse kidney events; NGAL, neutrophil gelatinase-associated lipocalin.

Ann Lab Med 2021;41:357~365 https://doi.org/10.3343/alm.2021.41.4.357